Replies to post #89917 on $heff's $tation of $tocks & $olid DD

[BioHunter]

$RPRX Chimaera great recap on the company. Adcom is going to be interesting as the FDA seems to be taking a more cautionary view of the long term risks of Low-T replacement. Post approval CV and stroke risk trials could be very costly as well.

Thanks for your DD contribution

-BIoHunter